Trellis AI vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 40)
Trellis AI logo

Trellis AI

EmergingHealthcare

General

SF YC Stanford AI Lab spinout healthcare automation at General Catalyst/Telesoft-backed; AI agents trained on millions of clinical data points automating prior authorization and document-to-EHR extraction for Fortune 500 providers competing with C...

AI VisibilityBeta
Overall Score
C40
Category Rank
#375 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
41
Perplexity
38
Gemini
42

About

Trellis AI is a San Francisco-based healthcare automation platform — backed by Y Combinator with funding from General Catalyst, Telesoft Partners, and executives from Google and Salesforce — providing healthcare providers, pharmaceutical companies, and diagnostic labs with AI agents trained on millions of clinical data points that convert unstructured medical documents into clean structured EHR data, automating the pre-service administrative workflows of document intake, prior authorization processing, and insurance appeal generation. Founded in 2024 as a Stanford AI Lab spinout by Mac Klinkachorn and Jacky Lin, Trellis serves Fortune 500 healthcare customers with a 25-person team focused on eliminating the manual paperwork that delays patient access to care.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
up
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

40
Overall Score
93
#375
Category Rank
#1
80
AI Consensus
80
stable
Trend
up
41
ChatGPT
94
38
Perplexity
89
42
Gemini
94
36
Claude
92
44
Grok
98

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.